Medicare Part D reimburses for “prescription only” drugs and does not reimburse for over-the counter-drugs, the Justice Department said in a Sept. 14 news release. Akorn admitted it delayed seeking the required conversions of three of its generic drugs from prescription only to over-the-counter status and continued to sell newly manufactured units of those drugs under the obsolete “prescription only” labeling.
Allegations were originally brought through a whistleblower complaint, according to the release. The whistleblower will receive $946,000 of the settlement money.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.